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Background/Objectives: Psoriasis is an inﬂammatory skin disease, which is associated with metabolic
syndrome and insulin resistance. Irisin is an adipokine and myokine that regulates the metabolic status
during times of increased insulin sensitivity. In this study, we aimed to investigate changes in the serum
level of irisin in psoriasis patients in comparison with participants who did not have any disease (control
group). We hope the results of our study would also aid in establishing a protocol aimed at under-
standing the etiopathogenesis and treatment of psoriasis.
Materials and methods: The study included 30 patients with psoriasis vulgaris, who presented to the
dermatology outpatient clinic and were not receiving systemic treatment. The control group included
voluntary participants who did not have any disease (n ¼ 30). In addition to venous and salivary irisin
levels, glucose, triglyceride, cholesterol, high-density lipoprotein, and low-density lipoprotein levels, and
Homeostasis Model Assessment of Insulin Resistance scores were measured in both control and patient
groups.
Results: Serum irisin and salivary irisin levels were signiﬁcantly lower in the patient group compared
with the control group (p < 0.05). In the patient group, serum irisin levels had a positive correlation with
salivary irisin levels (r ¼ 418; p ¼ 0.022) and a negative correlation with Psoriasis Area and Severity Index
(r ¼ 437, p ¼ 0.016) and Dermatological Life Quality Index (r ¼ 424; p ¼ 0.02) scores.
Conclusion: This is the ﬁrst study evaluating irisin levels in patients with psoriasis vulgaris in the liter-
ature. The results of our study show that serum and salivary irisin levels were signiﬁcantly lower in the
patient group when compared with the control group. Irisin levels in patients with severe psoriasis were
low, suggesting that irisin may have a role in the pathogenesis of psoriasis and may be a marker showing
the severity of psoriasis, which could warn us against the development of insulin resistance and diabetes
mellitus.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Psoriasis is a chronic, hyperproliferative inﬂammatory disease of
the skin, which is clinically characterized by erythematous andiasis Symposium held on April
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al Association. Published by Elsevisquamous plaques. The disease is associated with a genetic back-
ground.1 Because of the silvery, scaly appearance of the squamous
plaques, in Turkish it is called “nacre disease” in layman's terms.2,3
Psoriasis is observed in 1e3% of the general population.4
Irisin, ﬁrst discovered by Bostrom et al, is made up of 112 amino
acids.5 It is an adipokine and myokine, and exhibits autocrine and
paracrine effects. Irisin is mainly synthesized in skeletal muscle and
adipose tissue.5 Furthermore, irisin predominantly presents in pe-
ripheral nerve cells, sebaceous glands of the skin, as well as inmany
organs and tissues.6 It induces the conversion of white adipose
tissue into brown adipose tissue. In addition, it regulates thermo-
genesis, energy expenditure, weight loss, and ultimately glucose
homeostasis by increasing uncoupling protein 1 in brown adiposeer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
E.T. Alatas et al. / Dermatologica Sinica 35 (2017) 12e15 13tissue.6 Irisin, also called “exercise hormone,” is produced by the
cleavage of ﬁbronectin type III domain-containing protein 5
(FNDC5), the extracellular portion of type I membrane protein,
following activation by peroxisome proliferator-activated receptor-
g coactivator a.6 Proteins associated with insulin resistance, such as
adiponectin and ghrelin, are known to play a role in the patho-
genesis of psoriasis.7 Irisin is also a hormone associated with
obesity and glucose homeostasis. Patients with type 2 diabetes
mellitus (DM) have low levels of irisin. Moreover, irisin level has
been found to be decreased in nonalcoholic fatty liver disease and
heart failure.8
The association between psoriasis and insulin resistance is
known, and many studies in have been published in this area.9,10
However, none of these studies has evaluated irisin levels in pa-
tients with psoriasis. Our study is the ﬁrst study to examine irisin
levels in psoriasis aimed at understanding etiopathogenesis of the
disease. In our study, by measuring irisin levels in patients with
psoriasis, which is a disease associated with increased insulin
resistance, we evaluated whether irisin levels show any correlation
with severity of the disease. We hope our results would also aid in
establishing a protocol aimed at understanding the etiopatho-
genesis and treatment of psoriasis.Materials and methods
This study was conducted by the Dermatology Department of
Mugla Sitki Kocman University Faculty of Medicine. The study
included patients diagnosed with psoriasis vulgaris (n ¼ 30), who
presented to the dermatology outpatient clinic and were not
receiving systemic treatment (receiving topical therapy). The con-
trol group included voluntary participants who did not have any
disease (n ¼ 30). Individuals in both groups were informed about
the study protocol, and all participants provided written consent.
The study exclusion criteria were as follows: (1) other forms of
psoriasis such as pustular psoriasis or erythrodermic psoriasis; (2)
presence of any systemic disease (coronary artery disease, hepatic
failure, renal failure, malignancy, etc.); (3) pregnancy; (4) breast-
feeding; (5) younger than 18 years of age; and (6) receiving sys-
temic treatment.
All participants provided a detailed history. Age, duration of dis-
ease, presence of any other family member with psoriasis, smoking
status, and current treatment methods were questioned and noted
onpatient forms. Extent and severityof psoriasiswere assessedusing
the Psoriasis Area and Severity Index (PASI) scoring method and by
calculating the affected body surface area percentage.
Individuals in both the patient and control groups provided
3 mL of venous blood and 0.5 mL of saliva samples following
8e12 hours of fasting. Saliva samples were collected in sterile urine
cups. Blood and saliva samples were centrifuged at 4000 rpm for
10 minutes. The samples were then transferred to small-volume
tubes, and stored at 80C until further analysis. Irisin levels
were analyzed using enzyme linked-immunosorbent assay. In
addition to venous and salivary irisin levels, we also measured
glucose, triglyceride, cholesterol, high-density lipoprotein (HDL),
and low-density lipoprotein levels in both patient and control
groups. Insulin resistance was calculated according to the Ho-
meostasis Model Assessment of Insulin Resistance (HOMA-IR) for-
mula: fasting glucose (mmol/L)  fasting serum insulin (mIU/mL)/
22.5. In addition, body mass index (BMI) and Dermatological Life
Quality Index (DLQI) values were calculated.
Comparison of parameters between the two groups were made
with KolmogoroveSmirnov test and Student t test. Correlation of
parameters were analyzed with Spearman correlation test and p
values less than 0.05 was accepted as the level of signiﬁcance.Results
There were 15 males (50%) and 15 females (50%) in the patient
group, and 15 males (50%) and 15 females (50%) in the control
group. There was no statistically signiﬁcant difference between the
two groups in distribution of sex (p > 0.05). Mean age was
39.67 ± 9.30 years in the patient group, whereas it was
39.76 ± 15.74 years in the control group. Mean BMI was
27.73 ± 4.17 kg/m2 in the patient group, and 26.17 ± 3.81 kg/m2 in
the control group. There was no statistically signiﬁcant difference
between the patient and control groups regarding mean age and
BMI (p > 0.05). PASI scores in the patient group varied between 0.4
and 15.8, and the mean PASI score was 4.71 ± 3.52. The DLQI value
in the patient group varied between 0 and 26. The mean DLQI value
was 10.73 ± 7.82. Table 1 summarizes biochemical parameters,
insulin and hemoglobin A1c (HbA1c) levels, and HOMA-IR scores in
the patient and control groups.
Serum irisin and salivary irisin levels were signiﬁcantly lower in
the patient group when compared with the control group (p < 0.05;
Figure 1).
The patient group had signiﬁcantly higher serum glucose and
triglyceride levels, and signiﬁcantly lower HDL levels when
compared with the control group (p < 0.05; Figure 2).
The patient group had signiﬁcantly higher HbA1c levels and
HOMA-IR scores when compared with the control group (p < 0.05;
Figure 3).
In the patient group, serum irisin levels showed a positive cor-
relation with salivary irisin levels (r ¼ 418; p ¼ 0.022) and a
negative correlation with PASI (r ¼ 437; p ¼ 0.016) and DLQI
(r ¼ 424; p ¼ 0.02) values. Salivary irisin levels had a negative
correlation with PASI, but these correlations were not statistically
signiﬁcant (r¼351; p¼ 0.058). In addition, serum irisin levels had
a negative correlation with serum triglyceride levels and HOMA-IR
scores and a positive correlation with serum HDL levels; however,
these correlations were also not statistically signiﬁcant.
Discussion
Although the pathogenesis of psoriasis is not fully understood,
activation of T lymphocytes and keratinocyte hyperproliferation are
given particular emphasis in pathogenesis. In addition, there is
evidence indicating a role of endothelial cells in pathogenesis in the
early period of psoriasis. The most commonly emphasized mech-
anism concerning pathogenesis of psoriasis involves activation of
T cells of the immune system. Activated T cells release cytokines
such as interferon-g or tumor necrosis factor-a (TNF-a), and in-
crease concentration of other immune effector cells, including
neutrophils, in the inﬂammation site.11 TNF-a additionally stimu-
lates vascular endothelial cell growth factor production in kerati-
nocytes, and induces secondary proliferation of epidermal and
vascular cells.12 Various studies have been performed to determine
the pathogenesis of psoriasis; however, its etiology is not yet clear.
Many studies have emphasized chronic inﬂammation in psoria-
sis.13,14 Recently, a strong association has been suggested to exist
between psoriasis and metabolic syndrome as well as one of its
components, insulin resistance.15,16 It has been suggested that cy-
tokines that are released during the chronic inﬂammation in pso-
riasis may lead to the development of metabolic syndrome. One
study emphasized the presence of a strong correlation between
severity of psoriasis and insulin resistance. Furthermore, it drew
attention to psoriasis not only as a disease of the skin, but also as a
metabolic disease.17
Adipocytes are described as newly introduced members of the
immune system, as they release cytokines such as interleukin 6 and
TNF-a in addition to adipokines such as irisin, adiponectin, and
Table 1 Sociodemographic characteristics and biochemical parameters of the pa-
tient and control groups.
Psoriasis
(n ¼ 30)
Control
(n ¼ 30)
p
Age (y) 39.67 ± 9.30 39.76 ± 15.74 >0.05
Sex (female/male) 15/15 15/15 >0.05
Body mass index (kg/m2) 27.73 ± 4.17 26.17 ± 3.81 >0.05
Glucose (mg/dL) 93.06 ± 10.85 87.03 ± 7.62 <0.05
Hemoglobin A1c (%) 5.52 ± 0.53 5.17 ± 0.51 <0.05
Cholesterol (mg/dL) 214.56 ± 34.77 201.8 ± 35.22 >0.05
High-density lipoprotein (mg/dL) 44.46 ± 8.27 49.47 ± 9.51 <0.05
Low-density lipoprotein (mg/dL) 134.4 ± 23.89 123.07 ± 28.22 >0.05
Triglyceride (mg/dL) 181.5 ± 79.45 146.43 ± 49.02 <0.05
Insulin (mIU/mL) 7.39 ± 1.85 6.55 ± 2.01 >0.05
Homeostasis Model Assessment
of Insulin Resistance
1.87 ± 1.05 1.44 ± 0.41 <0.05
Serum irisin (ng/mL) 257.12 ± 67.33 292.39 ± 31.81 <0.05
Salivary irisin (ng/mL) 333.52 ± 81.08 381.07 ± 78.75 <0.05
Figure 2 Serum glucose, cholesterol, high-density lipoprotein (HDL), low-density li-
poprotein (LDL), and triglyceride levels of the patient and control groups. * p < 0.05
compared with the control group.
E.T. Alatas et al. / Dermatologica Sinica 35 (2017) 12e1514leptin.18 Discovered by Bostr€om et al, irisin is made up of 112 amino
acids, and is synthesized in the muscular tissue. White adipose
tissue also secretes FNDC5/irisin; therefore, irisin also behaves as an
adipokine and induces the browning of white adipose tissue and
protects against diet induced obesity and diabetes.5,19 Interestingly,
the concentration of irisin rises remarkably following exercise in
both mice and humans. Some animal model studies have shown
that irisin prolongs life span, reduces body weight by increasing
total energy expenditure, and decreases insulin resistance caused
by diet-induced obesity.5
By contrast, one study involving patients with polycystic ovary
syndrome, which is a disease associated with increased insulin
resistance, reported signiﬁcantly increased irisin levels in these
patients. This result was interpreted as a protective mechanism
against development of DM in patients with polycystic ovary syn-
drome.8 In addition, Park et al20 found increased levels of irisin in
patients with metabolic syndrome. In Behçet's disease, which is
characterized by endothelial dysfunction and atherosclerosis that
are triggered by hyperglycemia and chronic inﬂammation, irisin
levels were found to be low. It was stated that lower irisin levels
could be related to atherosclerosis. A negative correlation was
observed between irisin levels and HOMA-IR scores.21 In our study,
although we also found a negative correlation between irisin levels
and HOMA-IR scores, this was not statistically signiﬁcant.
There is a strong association between psoriasis and insulin
resistance, suggesting a possible role for irisin in etiopathogenesis
of psoriasis, as irisin is known to reduce weight by increasing total
energy expenditure, and decrease insulin resistance caused byFigure 1 Serum and salivary irisin levels of the patient and control groups.* p < 0.05
compared with the control group.diet.22 The serum irisin levels were found to be decreased in pa-
tients with type 2 DM, and this was associated with insulin resis-
tance.23,24 One study involving 581 patients with psoriasis found a
signiﬁcant association between psoriasis and type 2 DM.25 Another
study found signiﬁcantly increased insulin levels and HOMA-IR
scores in patients with psoriasis vulgaris.26 Naldi et al27 observed
a signiﬁcant association between BMI and psoriasis. In our study,
there was no signiﬁcant association between psoriasis and BMI;
however, there was a signiﬁcant association between psoriasis and
levels of glucose and HbA1c, as well as HOMA-IR scores.
Some studies have found a positive correlation between irisin
and low-density lipoprotein cholesterol.24 Wen et al28 detected a
positive correlation between irisin and HDL levels in patients with
chronic renal failure. Similar to our results, Icli et al21 did not ﬁnd
any correlation between irisin and lipid proﬁle.
Cytokines such as TNF-a have important roles in the patho-
genesis of psoriasis. As is already known, TNF-a is an important
cytokine for inﬂammatory, infectious, and malignant states. TNF-a
has been found to be elevated in the serum of patients with pso-
riasis, and in psoriatic skin. Furthermore, TNF-a level has been
shown to decrease in serum and skin lesion following treatment.
Moreover, TNF-a antagonists are effectively used in the treatment
of psoriasis.29 In one study with mice model, following short-term
administration of the cytokines TNF-a and interleukin-1b to mice,
an inﬂammatory state was induced, which reduced the release of
irisin from skeletal muscle.30 Signaling pathways leading to psori-
asis development are, however, not fully clear yet; one study hasFigure 3 Levels of serum hemoglobin A1c (HbA1C) and insulin, and Homeostasis
Model Assessment of Insulin Resistance (HOMA-IR) scores of the patient and control
groups. * p < 0.05 compared with the control group.
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might cause development of metabolic syndrome in patients with
psoriasis.31 Moreover, peroxisome proliferator-activated receptor-g
coactivator a plays a primary role in lipid and carbohydrate meta-
bolism and inﬂammation, and irisin synthesis is regulated through
its activation.30,32
Previous studies showed that parotid, sublingual and subman-
dibular glands produce and release irisin into saliva.33 Salivary iri-
sin levels were found to be elevated in patients with PradereWilli
syndrome, whereas they were found to be reduced and correlated
with serum irisin levels in patients who had acute myocardial
infarction.33,34 In our study, salivary irisin levels were low. Our
study demonstrates that rather than using invasive methods, irisin
levels can also be measured in the saliva of patients with psoriasis.
Conclusion
Pathogenesis of psoriasis and its relationship with insulin resis-
tance are not clearly understood. There are many studies demon-
strating insulin resistance in patients with psoriasis. However, no
previous study has evaluated irisin levels and its association with
insulin resistance in patients with psoriasis. Our study is the ﬁrst
study to examine irisin levels in patients with psoriasis. We found
lower serum and salivary irisin levels in these patients, which
indicate that irisin levels can also bemeasured in saliva, rather than
in serum. We also found a negative correlation between serum
irisin levels and the severity of psoriasis.
In conclusion, our results suggest that irisin may have a role in
the pathogenesis of psoriasis, and may be a marker showing the
severity of psoriasis, which could warn us against development of
insulin resistance and DM. There is a need for future large-scale
studies that investigate the association of irisin with the immune
system and metabolic parameters in patients with psoriasis.
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